Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026)

Aquestive Therapeutics' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$52000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 61.48% year-over-year to -$52000.0; the TTM figure through Mar 2026 stood at -$479000.0 (down 80.75% YoY), while the FY2025 annual figure was -$562000.0, down 253.46% from the prior year.
• Cash from Investing Activities was -$52000.0 for Q1 2026 at Aquestive Therapeutics, up from -$85000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q1 2023 to a low of -$1.7 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$252470.6 across 5 years, with a median of -$85000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 1968.67% in 2022, then soared 98.08% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$26000.0 in 2022, then soared by 38.46% to -$16000.0 in 2023, then climbed by 6.25% to -$15000.0 in 2024, then sank by 466.67% to -$85000.0 in 2025, then jumped by 38.82% to -$52000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$52000.0 (Q1 2026), -$85000.0 (Q4 2025), and -$235000.0 (Q3 2025), per Business Quant data.